Johnson & Johnson to Present Results of Its Covid-19 Vaccine Next Week

The approval of the new vaccine would come as the United States seeks to accelerate its immunization rate Source: .

«Johnson & Johnson (J&J) awaits report the results of the highly anticipated clinical trial on its Covid-19 vaccine next week«, Joseph Wolk, financial director of the American pharmaceutical company, told CNBC on Tuesday.

The company is expected to request, at the same time, the emergency clearance for your one-dose immunizer, shortly after, it could become the third vaccine to be authorized by the authorities in the United States.

« We plan to report early in the week on our results »said the company executive. He also highlighted that the phase 3 study of 45,000 people in 80 countries potentially included cases of the new strains identified in Brazil and South Africa.

« In terms of supply, we are very confident and on track to meet all of our commitments »Wolk added that they estimate the production of 100 million doses for the United States before the end of June, about 200 million doses before the end of the year for the European Union, with shipments due to begin in April. Another 200 million doses will be destined for developing countries, which would start shipping in the second half of the year.

The approval of this new vaccine would come at a time when the United States seeks to accelerate its immunization rate, since the new goal of the brand new president, Joe Biden, is to reach 1.5 million injections per day.

Biden announced his new goal on Monday, surpassing his previous goal of reaching 100 million injections in the first 100 days of his administration.


Like vaccines from American laboratories Pfizer and Modern, J & J’s sends genetic instructions to human cells to create a specific protein against coronavirus, with the goal of training the immune system for the live virus.

Pfizer and Moderna use single-stranded RNA molecules, while J & J’s vaccine unfolds double-stranded DNA that is converted into RNA within human cells to achieve the same goal.

DNA carries a modified and unreplicated version of a cold common cause of adenovirus. This virus acts as vehicle for delivering genetic cargo into the nucleus of human cells.

The AstraZeneca, Sputnik and CanSino vaccines use a similar technique, known as « adenoviral vector vaccines. »

They are more resistant than immunizing RNA pointers and can be stored in refrigerator temperatures, so they do not require special freezers.

In October, the American pharmaceutical company had to temporarily suspend the clinical trial of its vaccine against Covid-19 because one of its participants became ill. « We have temporarily halted the administration of new doses in all of our clinical trials of the vaccine, including the Phase 3 Ensemble trial, due to unexplained illness in one study participant, » he said in a statement at the time.

. Agency

According to the criteria of